The Estée Lauder Companies Announces Cedric Prouvé, Group President, International, to Retire After Exceptional Career
Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that after 27 years with the company, Cedric Prouvé, Group President, International, has made the decision to retire effective June 30, 2022. The successor to Cedric’s role will be announced shortly, and Cedric will partner with this individual starting in February 2022 to support a smooth and successful transition.
A visionary and highly-respected global leader, Cedric has, alongside his outstanding global teams, led ELC’s winning international business – including all sales and profits outside of North America, all activities of sales affiliates and distributor relationships worldwide, as well as the Travel Retail business – since 2003. Throughout his exceptional career, Cedric has been instrumental in elevating and operationalizing the company’s global network of Region Presidents and Affiliate General Managers, and has collaborated closely with Group and Brand Presidents and Function Leaders to integrate global marketing strategies in international markets.
Under Cedric’s leadership, ELC’s international business has grown significantly since 2003 – from approximately 43% of the business to approximately 77% of the business in fiscal year 2021. During his tenure, the company’s international organization has expanded to over 35 affiliates doing business in 150+ countries and territories across our international footprint, with strategic investments in talent, third-party relationships, and innovation pipelines in established and emerging markets.
“In a rapidly-changing industry, Cedric’s strategic vision, inspiring leadership style and unique team-building abilities have been integral to the success of ELC’s International business, and we are well-positioned for future growth,” said Fabrizio Freda, President and Chief Executive Officer. “I have greatly enjoyed my close partnership with Cedric over the years, and I would like to thank him for leading our International organization with a great blend of enthusiasm, thoughtfulness, and most especially, kindness. His positive energy, dynamic style, caring nature and deep international expertise will be truly missed.”
Among Cedric’s many accomplishments, he played a key role in establishing the company’s International structure, helping to develop and implement ELC’s successful regional and affiliate framework. Within that structure, he has built a diverse team of outstanding global and local experts, nurturing deep and lasting relationships with Region Presidents and Affiliate General Managers around the world, and fostering close ties with key global retailers and commercial partners.
During his tenure, Cedric sponsored many enterprise-wide initiatives and strategic transformational priorities to help ensure the company is building the right capabilities in the Asia/Pacific (APAC) Region and in China, its second home market. From the earliest days of this strategic work, Cedric helped to shape the value chain proposition that ultimately resulted in the implementation of ELC’s new Shanghai Innovation Center and its Japan-based manufacturing facility, both of which will be instrumental in continuing to position the company for long-term growth in the region and globally.
Since joining ELC in 1994, Cedric’s career trajectory has included leadership roles spanning regions, affiliates and business areas. He joined the company as General Manager (GM) for Travel Retail in the APAC Region, and soon thereafter added the responsibility of GM for the Singapore affiliate. He also served as Vice President, GM, Travel Retail Worldwide, navigating a wide range of challenges while proactively managing opportunities arising from the introduction of new brands and specialized marketing programs for the Travel Retail channel. Prior to his promotion to Group President, International, Cedric was the President and GM of the Japan affiliate.
“Throughout his career, Cedric’s keen ability to lead with our company values and foster meaningful partnerships across the enterprise has led to significant contributions across the business, while also enriching our company’s culture,” said William P. Lauder, Executive Chairman. “We have all benefitted from Cedric’s strategic insights and his candid and charismatic communication style. On behalf of the company and the Lauder family, I would like to wish Cedric the very best in his well-deserved retirement.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005441/en/
Contact information
Investors: Rainey Mancini
rmancini@estee.com
Media: Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
